Poly Medicure Limited — PPTs, 25-05-2026: Investor Presentation

**Business Performance:** Consolidated revenue for FY26 was up 12.3% YoY to 1,875 Cr. Domestic sales jumped 19.6%, and international revenue grew 9.3%, with standalone Q4 hitting a new record. Renal care and 'Others' segments showed strong growth.

**Growth Strategy:** Acquisitions like Citieffe (Orthopaedics) and PendraCare (Cardiology) are expanding market & tech. The company plans to double R&D spend, launching new products yearly, and building two new Indian plants for Medtech localization & cost optimization.

**Recent Highlights:** FY26 saw 35 new product launches, over 11,000 stent deployments, and initial sales of Drug Eluting Balloons (DEB). Dialysis machine installed base reached ~1000. Management focuses on high-growth segments and boosting 'Made in India' products.

**Financial Snapshot:** Consolidated Operating EBITDA was 458 Cr (24.4% margin), PAT 321 Cr. Standalone Operating EBITDA hit 26.8%, meeting guidance. Liquidity is strong at 842.2 Cr, with Return on Invested Capital (ROIC) firm at 21.2%.